A plain-language, continually updated guide from Dr. Matt Chalmers’ clinical reference on hormones and peptides.
Sermorelin is a synthetic 29-amino-acid analog of the first section of your body’s own growth-hormone-releasing hormone (GHRH). Rather than adding growth hormone directly, it signals your pituitary gland to make and release your own — which is a meaningfully different, more physiological approach. It has the longest clinical track record of any growth hormone secretagogue in US compounding medicine: it was originally FDA-approved as Geref for pediatric growth hormone deficiency, and manufacturing was discontinued in 2008 for business reasons, not safety concerns.
Because Sermorelin’s effect only lasts 10–20 minutes in the body, it produces short, discrete GH pulses that closely mimic your body’s natural nighttime rhythm — and importantly, your body’s own IGF-1 feedback loop stays intact, meaning it self-limits how much GH gets released. That built-in safety brake is the fundamental advantage this approach has over injecting growth hormone directly.
Sermorelin is almost always paired with Ipamorelin, since the two work through entirely different signaling pathways in the pituitary and produce a stronger combined effect than either alone. It’s worth knowing that long-term use may actually upregulate GHRH receptor expression over time, which could help preserve your GH secretory capacity as you age — rather than blunting it, as some worry peptide use might do. Whether Sermorelin fits your goals, and how it’s dosed and timed, is something our providers work out with you individually based on labs and your health history.
Zinc is required for GH pulsatility and pituitary GH synthesis directly; vitamin D modulates GHRH receptor sensitivity; magnesium is needed for the cAMP signaling cascade Sermorelin relies on. Sleep quality is arguably the most important non-pharmacological factor, since the majority of natural GH release happens during deep sleep — and adequate dietary protein is essential for the downstream, IGF-1-mediated benefit to actually materialize.
Sermorelin was previously FDA-approved (as Geref®) for pediatric growth hormone deficiency and was voluntarily discontinued from the market in 2008 for business reasons, not safety concerns. It is not currently FDA-approved for adult use; use in adults is considered off-label and is available through licensed 503A compounding pharmacies with a valid prescription. As with all growth-hormone-axis compounds, active or suspected malignancy is treated as a contraindication, and the FDA has issued specific warnings about the potential for immunogenicity (including anaphylaxis) with this class of peptide.
Yes — growth hormone is well established in endocrine physiology to have two relevant actions: it promotes lipolysis (breakdown of stored fat), and it raises IGF-1, which drives protein synthesis, the process underlying muscle tissue growth and repair. These are textbook actions of growth hormone itself, documented in endocrinology literature independent of any specific product.
These peptides work by stimulating the pituitary gland to release more of the body’s own growth hormone — they don’t introduce growth hormone directly. Because of this, any downstream effect on fat metabolism or muscle tissue would be expected to work through the same natural GH/IGF-1 pathway described above. Individual results depend on many factors, including diet, exercise, sleep, and baseline hormone levels, and are not guaranteed for any specific person. This is why our protocols pair peptide therapy with nutrition, training, and sleep support, rather than treating the peptide as a stand-alone solution.
Learn more about the pathway Sermorelin works within: Growth Hormone & IGF-1. Often paired with Ipamorelin, or compare with Tesamorelin and Hexarelin.
This page draws on The Pillars Path: A Root-Cause Guide to Hormones, Peptides, and Metabolic Health by Dr. Matt Chalmers — Pillars of Wellness’ clinical reference on hormone and peptide therapy.
